A notable advancement in blood sugar management is emerging with the approval of tirzepatide at a dosage of 45mg. This innovative version builds upon the existing success of tirzepatide, a dual GIP and GLP-1 agonist, https://bookmarkextent.com/story23416734/revolutionary-approach-tirzepatide-dose-for-glucose-control